{"source_content":"请务必阅读正文之后的免责条款部分1/8[Table_Main]公司研究|医疗保健|制药、生物科技与生命科学证券研究报告昊海生科(688366)公司点评报告2021年03月28日[Table_Title]眼科医美双轮驱动，助力公司重回高增长——昊海生科2020年报点评[Table_Summary]事件：2021年3月26日，公司公告：2020年年报：报告期内实现营收13.32亿元，同比下滑16.95%，归母净利润2.30亿元，同比下降37.95%。同时公告，拟向全体股东每10股派发现金红利人民币5.00元。分季度来看，公司2020年H1受疫情影响显著，H2明显复苏并呈现增长态势。分板块来看，受疫情影响手术量和门诊服务下滑，眼科与医美等板块承压。随着疫情逐步放缓可控，公司业务逐步恢复，四大板块均有望实现高增长。3月26日披露21年一季度业绩预告，预计归母净利润同比扭亏为盈，达到0.8-1亿元，扣非净利润0.75-0.95亿元，2021年业绩可期。眼科板块：布局逐步完善，白内障手术和全年龄段屈光矫正后续发力公司在眼科布局齐全，是中国最大的人工晶状体生产商，销售量市占率30%；同时是国内最大的眼科粘弹剂生产商，2020年中国市场份额为45.85%、连续13年超过四成。2020年公司人工晶状体产品、视光材料、眼科粘弹剂产品分别实现营业收入3.31、1.33、0.85亿元，相比分别下降23.62%、12.87%、25.13%，出现明显下滑。随着疫情逐步放缓可控，未来白内障手术和屈光矫正仍是长期向上发展趋势。公司在人工晶状体行业已完成全产业链布局；同时公司通过自主研发和外延并购方式，不断扩充成人和儿童屈光矫正产品。公司在2021年不断加码眼科行业投入，未来公司凭借眼科深入布局，有望实现新增长点。医美板块：“玻尿酸+肉毒毒素+光电设备”组合随着2020年8月“海魅”上市销售，目前公司拥有主打塑形功能的“海薇”、主打组织填充功能的“姣兰”及主打精准雕饰功能的“海魅”三款低中高端玻尿酸，在产品特点和功效方面形成差异化定位和互补式发展，满足日趋细分化、多元化的医美市场需求，随着海魅商业化推广进一步发力，预期将为公司业绩带来一定贡献。同时公司通过外延并购进军射频及光电类设备，扩充肉毒毒素产品，医美板块未来可期。投资建议与盈利预测考虑到公司2020业绩受疫情影响基数较低，同时2021年公司已不断通过并购优质标的，强化在眼科和医美板块布局，对业绩有显著提振，预计公司21-23年营收为18.53/24.51/30.82亿元，归母净利润为4.29/6.08/7.73亿元，EPS分别为2.42/3.43/4.36元/股，对应PE43/31/24，维持至增持评级。风险提示医美整顿影响超过预期；疫情影响超过预期；耗材集采降价风险；产品竞争加剧，产品研发不及预期。[Table_Finance]附表：盈利预测财务数据和估值201920202021E2022E2023E营业收入(百万元)1604.331332.431853.292451.473081.77收入同比（%）2.94-16.9539.0932.2825.71归母净利润(百万元)370.78230.07429.39607.84773.44归母净利润同比(%)-10.56-37.9586.6341.5627.24ROE（%）6.804.197.219.4511.01每股收益（元）2.091.302.423.434.36市盈率(P/E)50.2781.0243.4130.6724.10资料来源：Wind,国元证券研究所[Table_Invest]增持|维持[Table_TargetPrice]当前价：105.19元[Table_Base]基本数据52周最高/最低价（元）：195.85/69.63A股流通股（百万股）：78.28A股总股本（百万股）：176.62流通市值（百万元）：8234.13总市值（百万元）：18578.88[Table_PicQuote]过去一年股价走势资料来源：Wind[Table_DocReport]相关研究报告《国元证券公司研究-昊海生科(688366)近期动态点评报告：医美眼科双管齐下，为公司提供新增长点》2021.03.23《国元证券公司研究-昊海生科（688366）2020年三季报点评：疫情影响减弱，Q3业绩修复向好》2020.10.28[Table_Author]报告作者分析师刘慧敏执业证书编号S0020520110001电话021-51097188邮箱liuhuimin@gyzq.com.cn0%46%91%137%183%3/306/289/2612/253/25昊海生科沪深300请务必阅读正文之后的免责条款部分2/8分季度来看，上半年受疫情影响显著，下半年明显复苏并呈现增长态势。公司Q1、Q2、Q3和Q4分别实现营业收入1.54亿元（-50.64%）、3.42亿元（-27.70%）、3.96亿元（+10.31%）和4.40亿元（-6.98%），归母净利润分别为-0.25亿元（-137.33%）、0.52亿元（-54.83%）、0.85亿元（24.30%）、1.17亿元（-1.93%）。公司一季度受疫情影响尤为显著，二季度随着国内基本控制新冠疫情的蔓延和传播，业绩快速恢复至去年同期的七成，下半年则进一步呈现出明显复苏和增长态势，三季度实现正增长，四季度小幅波动。同时，3月26日公司披露21年一季度业绩预告，预计归母净利润同比扭亏为盈，达到0.8-1亿元，扣非净利润0.75-0.95亿元。公司因疫情带来的阴霾已经逐步散去，2021年有望开启快速增长进程。分板块来看，受疫情影响手术量和门诊服务下滑，眼科与医美等板块承压。2020年公司眼科产品实现收入5.66亿元（-20.62%），占比为42.49%；整形美容与创面护理产品实现收入2.42亿元（-19.33%），占比为18.17%；骨科产品实现收入3.32亿元（-7.52%），占比为24.92%；防粘连及止血产品实现收入1.72亿元（-9.47%），占比为12.91%；其他产品实现收入0.21亿元（-50%），占比1.58%。各子板块均有不同程度的下滑，主要系2020年疫情爆发导致公司业务涉及的眼科、择期手术、非急诊外科手术及骨关节腔注射等慢性病诊疗服务、医美门诊都纳入停诊或暂停服务。随着后疫情时代的到来，公司业务逐步恢复，四大板块均有望实现高增速。受到以上板块调整因素，2020年毛利率为74.93%，同比下降2.38pct。主要系毛利率较高的玻尿酸业务营收占比下降较大所致。在疫情、医美终端行业监管力度趋严等多重影响下，国内医美机构自身业务及其对玻尿酸的需求受到显著影响，玻尿酸产品销售数量减少，业务占比下滑。公司具有线性无颗粒特征的第三代玻尿酸产品“海魅”获得药监局批准，2020年8月上市销售，进一步完善了公司玻尿酸产品组合。海魅定位于高端，主打精准雕饰功能，由于其抗高温、抗酶解、无颗粒化及高内聚性特点，预计在人体内具有更长的填充和支撑时间，有望为后续成长性提供助力，提升高毛利的玻尿酸业务占比。营收、毛利率下滑，销售费用、研发费用提升，以及各项经营费用支出维持相对高位，利润收窄，归母净利润下降。2020年公司实现归母和扣非归母分别为2.30亿元和2.06亿元，同比分别下降37.95%和42.25%。净利率为16.99%，同比下降6.47pct，主要系：（1）销售费用增长约1200万：2020年，虽然受到疫情的影响，线下市场活动在第一季度几近停滞，但在疫情得到基本控制后，公司自第二季度开始持续进行市场和营销活动的投入，并积极开展线上推广活动，维护市场份额，强化和加深市场对公司产品特别是新产品的认可度，因此销售费用整体较2019年度略有增长。当期销售费用达5.56亿元，较2019年同比增长2.21%，销售费用率也提高7.79pct至41.71%。（2）研发费用增长约1000万：因加大对眼科和医美新产品的投入，当期公司研发费用达1.26亿元，较2019年增长8.6%，研发占比也提高2.23pct至9.46%；32488518/47054/2021032819:53请务必阅读正文之后的免责条款部分3/8公司在眼科和玻尿酸产品方面研发进展顺利。公司2020年研发投入较大，眼科板块和玻尿酸板块均取得进展：（1）在白内障治疗领域，自主研发的创新疏水模注工艺非球面人工晶状体产品，已于2020年9月在国内启动临床试验。该产品系可折叠、疏水性丙烯酸酯、单焦、非球面人工晶状体，用于矫正白内障超声乳化手术中无晶状体眼的视力，于2021年1月获得欧盟CE认证证书，成功将产品线拓展至疏水系列人工晶状体产品线。（2）在近视防控及屈光矫正领域，公司研制的新型角膜塑形镜产品于2020年1月启动临床试验，目前正有序推进。第二代PRL产品房水通透型有晶体眼后房人工晶状体进入注册检验阶段，相较前一代产品，该产品将实现房水循环，并能够提供更为宽泛的视力矫正范围。（3）在眼表治疗领域，公司研制的盐酸莫西沙星滴眼液于2021年3月获得国家药监局批复的产品注册证书，该产品是第四代氟喹诺酮类药物，为细菌性结膜炎治疗的主流用药之一。用于眼科手术局部麻醉的盐酸利多卡因眼用凝胶，已处于申报生产阶段。（4）在眼底治疗领域，公司眼内填充用线性交联透明质酸钠凝胶、新型人工玻璃体等研发项目持续推进。其中，用于封堵视网膜裂孔治疗孔源性视网膜脱离的产品“眼内填充用线性交联透明质酸钠凝胶”，已于2020年7月启动临床试验。（5）在医美板块，具有线性无颗粒特征的第三代玻尿酸产品“海魅”，已于2020年2月获得国家药监局批准注册，并于2020年8月正式上市销售。该产品主打“精准雕饰”功能，其独特的无颗粒化结构不仅能够带来高内聚力，还能够减缓透明质酸的生物降解，从而使注射效果更为持久，同时可以防止生物膜的产生，降低不良反应发生率，大大提高产品的安全性。2020年11月，公司在研的第四代有机交联玻尿酸产品进入临床试验阶段。该产品使用天然产物为交联剂，降解产物为不能合成的人体必需氨基酸，相较于传统化学交联剂，具有更好的远期安全性。此外，该产品为国内首个封闭透明质酸酶作用位点的产品，具有更为长效的特质。表1：2020年公司新产品及研发重大进展序号事件1可折叠、疏水性丙烯酸酯、单焦、非球面人工晶状体于2020年9月在国内启动临床试验，并于2021年1月获得欧盟CE认证证书2新型角膜塑形镜产品于2020年1月启动临床试验3第二代PRL产品房水通透型有晶体眼后房人工晶状体进入注册检验阶段4酸莫西沙星滴眼液于2021年3月获得国家药监局批复的产品注册证书5盐酸利多卡因眼用凝胶，已处于申报生产阶段6眼内填充用线性交联透明质酸钠凝胶、新型人工玻璃体等研发项目已于2020年7月启动临床试验7具有线性无颗粒特征的第三代玻尿酸产品“海魅”，于2020年8月正式上市销售8在研的第四代有机交联玻尿酸产品2020年11月进入临床试验阶段资料来源：公司年报、国元证券研究所32488518/47054/2021032819:53请务必阅读正文之后的免责条款部分4/8眼科布局逐步完善，有望后续发力：公司在眼科布局齐全，已成为中国最大的人工晶状体生产商，按销售数量计算，市场份额为30%；公司已成为中国最大的眼科粘弹剂生产商，2020年中国市场份额为45.85%、连续13年超过四成。2020年公司人工晶状体产品、视光材料、眼科粘弹剂产品分别实现营业收入3.31亿元、1.33亿元和0.85亿元，与2019年相比分别下降23.62%、12.87%、25.13%，出现明显下滑。随着疫情逐步放缓可控，未来白内障手术和屈光矫正仍是长期向上发展趋势。公司在人工晶状体行业已完成全产业链布局；同时公司通过自主研发和外延并购方式，不断扩充成人和儿童屈光矫正产品；其次公司在2021年不断加码眼科行业投入，未来公司凭借眼科深入布局，有望实现新增长点。（1）2020年4月将用于成年人近视矫正的国产唯一一款屈光晶体依镜®PRL纳入昊海眼视光版图之后，昊海生科进一步拓展完善青少年近视防控产品线。（2）战略合作亨泰，取得目前国内最高透氧率的OK镜产品——迈儿康®myOK®独家经销权，能够为全年龄段人群提供近视解决方案。（3）可折叠、疏水性丙烯酸酯、单焦、非球面人工晶状体获得CE认证，成为国内唯一同时掌握亲水和疏水两种工艺路线且拥有获准上市销售产品的人工晶状体制造商。（4）公司自研盐酸莫西沙星滴眼液获NMPA批准注册，成为国产首仿。医美板块：“玻尿酸+肉毒毒素+光电设备”组合：（1）随着2020年8月“海魅”上市销售，目前公司拥有主打塑形功能的“海薇”、主打组织填充功能的“姣兰”及主打精准雕饰功能的“海魅”三款低中高端玻尿酸，在产品特点和功效方面形成差异化定位和互补式发展，满足日趋细分化、多元化的医美市场需求。（2）2021年2月收购欧华美科63.64%的股权，通过并购进军射频及光电类设备，公司的产品线拓展至物理类皮肤旋切设备，激光、射频类皮肤护理光电设备领域，并加强了玻尿酸及几丁糖生物医用材料创新研发能力和产品储备。同时借力欧华美科渠道优势，充分发挥协同效应，为公司医美产品终端销售提供有力支撑。（3）2021年3月认购Eirion约13.96%股权，通过投资获得了拓展“外用涂抹+经典注射”肉毒毒素产品以及白发脱发治疗药品未来在中国市场的商业化权利，进一步扩充和完善提高公司医疗美容产品线，推动公司医疗美容业务的发展。32488518/47054/2021032819:53请务必阅读正文之后的免责条款部分5/8图1：公司各板块产品布局情况资料来源：公司年报、国元证券研究所图2：公司营收和归母净利润及增速（亿元，%）图3：公司单季度营收和归母净利润及增速（亿元，%）资料来源：公司年报、wind、国元证券研究所资料来源：公司年报、wind、国元证券研究所-40%-20%0%20%40%60%80%02468101214161820162017201820192020营业收入归母净利润营收增速归母净利润增速-150%-100%-50%0%50%100%150%200%250%300%350%-101234519Q119Q219Q319Q420Q120Q220Q320Q4营业收入归母净利润营收增速归母净利润增速32488518/47054/2021032819:53请务必阅读正文之后的免责条款部分6/8图4：公司分业务营收占比（%）图5：公司毛利率和净利率情况（%）资料来源：公司年报、wind、国元证券研究所资料来源：公司年报、wind、国元证券研究所图6：公司期间费用率不断增长（%）图7：公司不断加码研发投入（亿元）资料来源：公司年报、wind、国元证券研究所资料来源：公司年报、wind、国元证券研究所投资建议与盈利预测考虑到公司2020业绩受疫情影响基数较低，同时2021年公司已不断通过并购优质标的，强化在眼科和医美板块布局，对业绩有显著提振，预计公司21-23年营收为18.53/24.51/30.82亿元，归母净利润为4.29/6.08/7.73亿元，EPS分别为2.42/3.43/4.36元/股，对应PE43/31/24，维持至增持评级。风险提示医美整顿影响超过预期；疫情影响超过预期；耗材集采降价风险；产品竞争加剧，产品研发不及预期。0.0%20.0%40.0%60.0%80.0%100.0%120.0%20162017201820192020眼科骨科产品整形美容与创面护理防粘连及止血其他收入0.00%10.00%20.00%30.00%40.00%50.00%60.00%70.00%80.00%90.00%20162017201820192020毛利率净利率-10.00%0.00%10.00%20.00%30.00%40.00%50.00%(2.00)(1.00)-1.002.003.004.005.006.0020162017201820192020管理费用销售费用财务费用管理费用率销售费用率财务费用率0%1%2%3%4%5%6%7%8%9%10%00.20.40.60.811.21.420162017201820192020研发费用研发费用率32488518/47054/2021032819:53请务必阅读正文之后的免责条款部分7/8[Table_FinanceDetail]财务预测表资产负债表单位:百万元利润表单位:百万元会计年度201920202021E2022E2023E会计年度201920202021E2022E2023E流动资产3945.383809.964496.075155.675967.03营业收入1604.331332.431853.292451.473081.77现金3222.513143.573658.364044.114570.88营业成本364.00334.00441.15591.19750.79应收账款381.99333.53416.99551.58693.40营业税金及附加9.269.6211.1217.1621.57其他应收款10.4511.6518.5324.5130.82营业费用544.13555.73667.18833.501016.98预付账款37.4343.7252.9470.9490.10管理费用266.56214.16296.53367.72462.27存货239.99255.13324.25434.52551.83研发费用116.08126.47140.00150.00160.00其他流动资产53.0122.3625.0030.0030.00财务费用-63.55-99.12-133.37-151.22-170.11非流动资产2206.492488.752349.642202.492035.41资产减值损失-0.56-3.970.500.500.50长期投资5.3350.2250.0050.0050.00公允价值变动收益0.000.000.000.000.00固定资产534.49532.30675.55688.65636.69投资净收益20.5736.8540.0040.0040.00无形资产613.99578.89538.89488.89428.89营业利润435.38259.01511.18723.62920.76其他非流动资产1052.681327.341085.21974.95919.83营业外收入0.020.440.000.000.00资产总计6151.876298.716845.717358.178002.43营业外支出1.052.430.000.000.00流动负债359.97433.77494.10505.81531.37利润总额434.35257.02511.18723.62920.76短期借款5.3078.69100.00100.00100.00所得税57.9730.6966.4594.07119.70应付账款36.7928.0348.5365.0382.59净利润376.38226.34444.73629.55801.06其他流动负债317.88327.04345.57340.78348.78少数股东损益5.60-3.7315.3421.7127.62非流动负债138.55130.70140.58140.58140.58归属母公司净利润370.78230.07429.39607.84773.44长期借款0.650.580.580.580.58EBITDA471.87277.43495.07719.55917.75其他非流动负债137.90130.12140.00140.00140.00EPS（元）2.081.302.423.434.36负债合计498.52564.46634.68646.40671.95少数股东权益198.57243.49258.83280.54308.16主要财务比率股本177.85177.21177.21177.21177.21会计年度201920202021E2022E2023E资本公积3281.593259.543259.543259.543259.54成长能力留存收益1935.542046.072475.462954.483545.57营业收入(%)2.94-16.9539.0932.2825.71归属母公司股东权益5454.785490.755952.216431.237022.32营业利润(%)-17.31-40.5197.3641.5627.24负债和股东权益6151.876298.716845.717358.178002.43归属母公司净利润(%)-10.56-37.9586.6341.5627.24获利能力现金流量表单位:百万元毛利率(%)77.3174.9376.2075.8875.64会计年度201920202021E2022E2023E净利率(%)23.1117.2723.1724.7925.10经营活动现金流348.91262.07265.68328.34499.02ROE(%)6.804.197.219.4511.01净利润376.38226.34444.73629.55801.06ROIC(%)14.086.2414.4920.9426.44折旧摊销100.04117.54117.26147.15167.09偿债能力财务费用-63.55-99.12-133.37-151.22-170.11资产负债率(%)8.108.969.278.788.40投资损失-20.57-36.85-40.00-40.00-40.00净负债比率(%)5.2915.6415.8515.5614.97营运资金变动-34.2151.89-143.14-274.34-277.18流动比率10.968.789.1010.1911.23其他经营现金流-9.172.2720.2017.2118.15速动比率10.298.188.439.3210.17投资活动现金流-1135.74316.9271.3935.0040.00营运能力资本支出399.30195.860.000.000.00总资产周转率0.300.210.280.350.40长期投资768.13-326.70-5.500.000.00应收账款周转率4.013.414.464.564.46其他投资现金流31.69186.0865.8935.0040.00应付账款周转率9.8910.3111.5210.4110.17筹资活动现金流1392.55-190.06177.7322.40-12.24每股指标（元）短期借款-13.5973.3921.310.000.00每股收益(最新摊薄)2.091.302.423.434.36长期借款-15.73-0.070.000.000.00每股经营现金流(最新摊薄)1.971.480.000.000.00普通股增加17.80-0.640.000.000.00每股净资产(最新摊薄)30.7830.9933.5936.2939.63资本公积增加1511.47-22.050.000.000.00估值比率其他筹资现金流-107.40-240.69156.4322.40-12.24P/E50.2781.0243.4130.6724.10现金净增加额608.88383.38514.80385.75526.78P/B3.423.393.132.902.65EV/EBITDA32.3254.9830.8121.2016.6232488518/47054/2021032819:5332488518/47054/2021032819:53","data":[{"id":"1","source_document":"昊海生科（688366）：眼科医美双轮驱动，助力公司重回高增长.pdf","content":"2020年年报：报告期内实现营收13.32亿元","content_offset":["167","190"],"indicators":[{"indicator_name":"营业收入","indicator_value":["13.32亿元","183","190"],"indicator_element":{"时间":["2020年","167","172"],"公司":["昊海生科","121","125"]},"indicator_supplement":{"属性":""}}]},{"id":"2","source_document":"昊海生科（688366）：眼科医美双轮驱动，助力公司重回高增长.pdf","content":"同比下滑16.95%","content_offset":["191","201"],"indicators":[{"indicator_name":"营业收入同比","indicator_value":["下滑16.95%","193","201"],"indicator_element":{"时间":["2020年","125","130"],"公司":["昊海生科","121","125"]},"indicator_supplement":{"属性":""}}]},{"id":"3","source_document":"昊海生科（688366）：眼科医美双轮驱动，助力公司重回高增长.pdf","content":"归母净利润2.30亿元","content_offset":["202","213"],"indicators":[{"indicator_name":"归母净利润","indicator_value":["2.30亿元","207","213"],"indicator_element":{"时间":["2020年","125","130"],"公司":["昊海生科","121","125"]},"indicator_supplement":{"属性":""}}]},{"id":"4","source_document":"昊海生科（688366）：眼科医美双轮驱动，助力公司重回高增长.pdf","content":"同比下降37.95%","content_offset":["214","224"],"indicators":[{"indicator_name":"归母净利润同比","indicator_value":["下降37.95%","216","224"],"indicator_element":{"时间":["2020年","125","130"],"公司":["昊海生科","121","125"]},"indicator_supplement":{"属性":""}}]},{"id":"5","source_document":"昊海生科（688366）：眼科医美双轮驱动，助力公司重回高增长.pdf","content":"预计归母净利润同比扭亏为盈，达到0.8-1亿元","content_offset":["376","399"],"indicators":[{"indicator_name":"归母净利润","indicator_value":["0.8-1亿元","392","399"],"indicator_element":{"时间":["21年","365","368"],"公司":["昊海生科","1719","1723"]},"indicator_supplement":{"属性":"预计"}}]},{"id":"6","source_document":"昊海生科（688366）：眼科医美双轮驱动，助力公司重回高增长.pdf","content":"扣非净利润0.75-0.95亿元","content_offset":["400","416"],"indicators":[{"indicator_name":"扣非归母净利润","indicator_value":["0.75-0.95亿元","405","416"],"indicator_element":{"时间":["21年","365","368"],"公司":["昊海生科","1719","1723"]},"indicator_supplement":{"属性":"预计"}}]},{"id":"7","source_document":"昊海生科（688366）：眼科医美双轮驱动，助力公司重回高增长.pdf","content":"预计公司21-23年营收为18.53/24.51/30.82亿元","content_offset":["1036","1068"],"indicators":[{"indicator_name":"营业收入","indicator_value":["","1036","1036"],"indicator_element":{"时间":["21-23年","1040","1046"],"公司":["昊海生科","1719","1723"]},"indicator_supplement":{"属性":""}},{"indicator_name":"营业收入","indicator_value":["","1036","1036"],"indicator_element":{"时间":["21-23年","1040","1046"],"公司":["昊海生科","1719","1723"]},"indicator_supplement":{"属性":""}},{"indicator_name":"营业收入","indicator_value":["30.82亿元","1061","1068"],"indicator_element":{"时间":["21-23年","1040","1046"],"公司":["昊海生科","1719","1723"]},"indicator_supplement":{"属性":""}}]},{"id":"8","source_document":"昊海生科（688366）：眼科医美双轮驱动，助力公司重回高增长.pdf","content":"归母净利润为4.29/6.08/7.73亿元","content_offset":["1069","1091"],"indicators":[{"indicator_name":"归母净利润","indicator_value":["","1069","1069"],"indicator_element":{"时间":["21-23年","1040","1046"],"公司":["昊海生科","1719","1723"]},"indicator_supplement":{"属性":""}},{"indicator_name":"归母净利润","indicator_value":["","1069","1069"],"indicator_element":{"时间":["21-23年","1040","1046"],"公司":["昊海生科","1719","1723"]},"indicator_supplement":{"属性":""}},{"indicator_name":"归母净利润","indicator_value":["7.73亿元","1085","1091"],"indicator_element":{"时间":["21-23年","1040","1046"],"公司":["昊海生科","1719","1723"]},"indicator_supplement":{"属性":""}}]},{"id":"9","source_document":"昊海生科（688366）：眼科医美双轮驱动，助力公司重回高增长.pdf","content":"EPS分别为2.42/3.43/4.36元/股","content_offset":["1092","1115"],"indicators":[{"indicator_name":"EPS","indicator_value":["","1092","1092"],"indicator_element":{"时间":["21-23年","1040","1046"],"公司":["昊海生科","1719","1723"]},"indicator_supplement":{"属性":""}},{"indicator_name":"EPS","indicator_value":["","1092","1092"],"indicator_element":{"时间":["21-23年","1040","1046"],"公司":["昊海生科","1719","1723"]},"indicator_supplement":{"属性":""}},{"indicator_name":"EPS","indicator_value":["4.36元/股","1108","1115"],"indicator_element":{"时间":["21-23年","1040","1046"],"公司":["昊海生科","1719","1723"]},"indicator_supplement":{"属性":""}}]},{"id":"10","source_document":"昊海生科（688366）：眼科医美双轮驱动，助力公司重回高增长.pdf","content":"对应PE43/31/24","content_offset":["1116","1128"],"indicators":[{"indicator_name":"PE","indicator_value":["","1116","1116"],"indicator_element":{"时间":["21-23年","1040","1046"],"公司":["昊海生科","1719","1723"]},"indicator_supplement":{"属性":""}},{"indicator_name":"PE","indicator_value":["","1116","1116"],"indicator_element":{"时间":["21-23年","1040","1046"],"公司":["昊海生科","1719","1723"]},"indicator_supplement":{"属性":""}},{"indicator_name":"PE","indicator_value":["","1116","1116"],"indicator_element":{"时间":["21-23年","1040","1046"],"公司":["昊海生科","1719","1723"]},"indicator_supplement":{"属性":""}}]},{"id":"11","source_document":"昊海生科（688366）：眼科医美双轮驱动，助力公司重回高增长.pdf","content":"公司Q1、Q2、Q3和Q4分别实现营业收入1.54亿元（-50.64%）、3.42亿元（-27.70%）、3.96亿元（+10.31%）和4.40亿元（-6.98%）","content_offset":["2006","2089"],"indicators":[{"indicator_name":"营业收入","indicator_value":["1.54亿元","2027","2033"],"indicator_element":{"时间":["2020年","2381","2386"],"公司":["昊海生科","1946","1950"]},"indicator_supplement":{"属性":""}},{"indicator_name":"营业收入","indicator_value":["3.42亿元","2043","2049"],"indicator_element":{"时间":["2020年","2381","2386"],"公司":["昊海生科","1946","1950"]},"indicator_supplement":{"属性":""}},{"indicator_name":"营业收入","indicator_value":["3.96亿元","2059","2065"],"indicator_element":{"时间":["2020年","2381","2386"],"公司":["昊海生科","1946","1950"]},"indicator_supplement":{"属性":""}},{"indicator_name":"营业收入","indicator_value":["4.40亿元","2075","2081"],"indicator_element":{"时间":["2020年","2381","2386"],"公司":["昊海生科","1946","1950"]},"indicator_supplement":{"属性":""}}]},{"id":"12","source_document":"昊海生科（688366）：眼科医美双轮驱动，助力公司重回高增长.pdf","content":"公司Q1、Q2、Q3和Q4分别实现营业收入1.54亿元（-50.64%）、3.42亿元（-27.70%）、3.96亿元（+10.31%）和4.40亿元（-6.98%）","content_offset":["2006","2089"],"indicators":[{"indicator_name":"营业收入同比","indicator_value":["-50.64%","2034","2041"],"indicator_element":{"时间":["2020年","2381","2386"],"公司":["昊海生科","1946","1950"]},"indicator_supplement":{"属性":""}},{"indicator_name":"营业收入同比","indicator_value":["-27.70%","2050","2057"],"indicator_element":{"时间":["2020年","2381","2386"],"公司":["昊海生科","1946","1950"]},"indicator_supplement":{"属性":""}},{"indicator_name":"营业收入同比","indicator_value":["+10.31%","2066","2073"],"indicator_element":{"时间":["2020年","2381","2386"],"公司":["昊海生科","1946","1950"]},"indicator_supplement":{"属性":""}},{"indicator_name":"营业收入同比","indicator_value":["-6.98%","2082","2088"],"indicator_element":{"时间":["2020年","2381","2386"],"公司":["昊海生科","1946","1950"]},"indicator_supplement":{"属性":""}}]},{"id":"13","source_document":"昊海生科（688366）：眼科医美双轮驱动，助力公司重回高增长.pdf","content":"归母净利润分别为-0.25亿元（-137.33%）、0.52亿元（-54.83%）、0.85亿元（24.30%）、1.17亿元（-1.93%）","content_offset":["2090","2161"],"indicators":[{"indicator_name":"归母净利润","indicator_value":["0.25亿元","2099","2105"],"indicator_element":{"时间":["2020年","2381","2386"],"公司":["昊海生科","5002","5006"]},"indicator_supplement":{"属性":""}},{"indicator_name":"归母净利润","indicator_value":["0.52亿元","2116","2122"],"indicator_element":{"时间":["2020年","2381","2386"],"公司":["昊海生科","5002","5006"]},"indicator_supplement":{"属性":""}},{"indicator_name":"归母净利润","indicator_value":["0.85亿元","2132","2138"],"indicator_element":{"时间":["2020年","2381","2386"],"公司":["昊海生科","5002","5006"]},"indicator_supplement":{"属性":""}},{"indicator_name":"归母净利润","indicator_value":["1.17亿元","2147","2153"],"indicator_element":{"时间":["2020年","2381","2386"],"公司":["昊海生科","5002","5006"]},"indicator_supplement":{"属性":""}}]},{"id":"14","source_document":"昊海生科（688366）：眼科医美双轮驱动，助力公司重回高增长.pdf","content":"归母净利润分别为-0.25亿元（-137.33%）、0.52亿元（-54.83%）、0.85亿元（24.30%）、1.17亿元（-1.93%）","content_offset":["2090","2161"],"indicators":[{"indicator_name":"归母净利润同比","indicator_value":["-137.33%","2106","2114"],"indicator_element":{"时间":["2020年","2381","2386"],"公司":["昊海生科","5002","5006"]},"indicator_supplement":{"属性":""}},{"indicator_name":"归母净利润同比","indicator_value":["-54.83%","2123","2130"],"indicator_element":{"时间":["2020年","2381","2386"],"公司":["昊海生科","5002","5006"]},"indicator_supplement":{"属性":""}},{"indicator_name":"归母净利润同比","indicator_value":["24.30%","2139","2145"],"indicator_element":{"时间":["2020年","2381","2386"],"公司":["昊海生科","5002","5006"]},"indicator_supplement":{"属性":""}},{"indicator_name":"归母净利润同比","indicator_value":["-1.93%","2154","2160"],"indicator_element":{"时间":["2020年","2381","2386"],"公司":["昊海生科","5002","5006"]},"indicator_supplement":{"属性":""}}]},{"id":"15","source_document":"昊海生科（688366）：眼科医美双轮驱动，助力公司重回高增长.pdf","content":"整形美容与创面护理产品实现收入2.42亿元（-19.33%）","content_offset":["2422","2452"],"indicators":[{"indicator_name":"收入","indicator_value":["2.42亿元","2437","2443"],"indicator_element":{"公司":["昊海生科","5002","5006"],"产品":["整形美容与创面护理产品","2422","2433"]},"indicator_supplement":{"属性":""}}]},{"id":"16","source_document":"昊海生科（688366）：眼科医美双轮驱动，助力公司重回高增长.pdf","content":"整形美容与创面护理产品实现收入2.42亿元（-19.33%）","content_offset":["2422","2452"],"indicators":[{"indicator_name":"收入同比","indicator_value":["-19.33%","2444","2451"],"indicator_element":{"公司":["昊海生科","5002","5006"],"产品":["整形美容与创面护理产品","2422","2433"]},"indicator_supplement":{"属性":""}}]},{"id":"17","source_document":"昊海生科（688366）：眼科医美双轮驱动，助力公司重回高增长.pdf","content":"2020年毛利率为74.93%","content_offset":["2687","2702"],"indicators":[{"indicator_name":"毛利率","indicator_value":["74.93%","2696","2702"],"indicator_element":{"时间":["2020年","2687","2692"],"公司":["昊海生科","5002","5006"]},"indicator_supplement":{"属性":""}}]},{"id":"18","source_document":"昊海生科（688366）：眼科医美双轮驱动，助力公司重回高增长.pdf","content":"同比下降2.38pct","content_offset":["2703","2714"],"indicators":[{"indicator_name":"毛利率同比","indicator_value":["下降2.38pct","2705","2714"],"indicator_element":{"时间":["2020年","2687","2692"],"公司":["昊海生科","5002","5006"]},"indicator_supplement":{"属性":""}}]},{"id":"19","source_document":"昊海生科（688366）：眼科医美双轮驱动，助力公司重回高增长.pdf","content":"2020年公司实现归母和扣非归母分别为2.30亿元和2.06亿元","content_offset":["3005","3037"],"indicators":[{"indicator_name":"归母净利润","indicator_value":["2.30亿元","3024","3030"],"indicator_element":{"时间":["2020年","3005","3010"],"公司":["昊海生科","5002","5006"]},"indicator_supplement":{"属性":""}}]},{"id":"20","source_document":"昊海生科（688366）：眼科医美双轮驱动，助力公司重回高增长.pdf","content":"2020年公司实现归母和扣非归母分别为2.30亿元和2.06亿元","content_offset":["3005","3037"],"indicators":[{"indicator_name":"扣非归母净利润","indicator_value":["2.06亿元","3031","3037"],"indicator_element":{"时间":["2020年","3005","3010"],"公司":["昊海生科","5002","5006"]},"indicator_supplement":{"属性":""}}]},{"id":"21","source_document":"昊海生科（688366）：眼科医美双轮驱动，助力公司重回高增长.pdf","content":"同比分别下降37.95%和42.25%","content_offset":["3038","3057"],"indicators":[{"indicator_name":"归母净利润同比","indicator_value":["下降37.95%","3042","3050"],"indicator_element":{"时间":["2020年","3005","3010"],"公司":["昊海生科","5002","5006"]},"indicator_supplement":{"属性":""}}]},{"id":"22","source_document":"昊海生科（688366）：眼科医美双轮驱动，助力公司重回高增长.pdf","content":"同比分别下降37.95%和42.25%","content_offset":["3038","3057"],"indicators":[{"indicator_name":"扣非归母净利润同比","indicator_value":["下降42.25%","-1","-1"],"indicator_element":{"时间":["2020年","3005","3010"],"公司":["昊海生科","5002","5006"]},"indicator_supplement":{"属性":""}}]},{"id":"23","source_document":"昊海生科（688366）：眼科医美双轮驱动，助力公司重回高增长.pdf","content":"净利率为16.99%","content_offset":["3058","3068"],"indicators":[{"indicator_name":"净利润","indicator_value":["16.99%","3062","3068"],"indicator_element":{"时间":["2020年","3005","3010"],"公司":["昊海生科","5002","5006"]},"indicator_supplement":{"属性":""}}]},{"id":"24","source_document":"昊海生科（688366）：眼科医美双轮驱动，助力公司重回高增长.pdf","content":"同比下降6.47pct","content_offset":["3069","3080"],"indicators":[{"indicator_name":"净利润同比","indicator_value":["下降6.47pct","3071","3080"],"indicator_element":{"时间":["2020年","3005","3010"],"公司":["昊海生科","5002","5006"]},"indicator_supplement":{"属性":""}}]},{"id":"25","source_document":"昊海生科（688366）：眼科医美双轮驱动，助力公司重回高增长.pdf","content":"当期销售费用达5.56亿元","content_offset":["3231","3244"],"indicators":[{"indicator_name":"销售费","indicator_value":["5.56亿元","3238","3244"],"indicator_element":{"时间":["2020年","3435","3440"],"公司":["昊海生科","5002","5006"]},"indicator_supplement":{"属性":""}}]},{"id":"26","source_document":"昊海生科（688366）：眼科医美双轮驱动，助力公司重回高增长.pdf","content":"较2019年同比增长2.21%","content_offset":["3245","3260"],"indicators":[{"indicator_name":"销售费同比","indicator_value":["2.21%","3255","3260"],"indicator_element":{"时间":["2020年","3435","3440"],"公司":["昊海生科","5002","5006"]},"indicator_supplement":{"属性":""}}]},{"id":"27","source_document":"昊海生科（688366）：眼科医美双轮驱动，助力公司重回高增长.pdf","content":"销售费用率也提高7.79pct至41.71%","content_offset":["3261","3283"],"indicators":[{"indicator_name":"销售费用率","indicator_value":["41.71%","3277","3283"],"indicator_element":{"时间":["2020年","3435","3440"],"公司":["昊海生科","5002","5006"]},"indicator_supplement":{"属性":""}}]},{"id":"28","source_document":"昊海生科（688366）：眼科医美双轮驱动，助力公司重回高增长.pdf","content":"当期公司研发费用达1.26亿元","content_offset":["3316","3331"],"indicators":[{"indicator_name":"研发费用","indicator_value":["1.26亿元","3325","3331"],"indicator_element":{"时间":["2020年","3435","3440"],"公司":["昊海生科","5002","5006"]},"indicator_supplement":{"属性":""}}]},{"id":"29","source_document":"昊海生科（688366）：眼科医美双轮驱动，助力公司重回高增长.pdf","content":"较2019年增长8.6%","content_offset":["3332","3344"],"indicators":[{"indicator_name":"研发费用同比","indicator_value":["8.6%","3340","3344"],"indicator_element":{"时间":["2020年","3435","3440"],"公司":["昊海生科","5002","5006"]},"indicator_supplement":{"属性":""}}]},{"id":"30","source_document":"昊海生科（688366）：眼科医美双轮驱动，助力公司重回高增长.pdf","content":"研发占比也提高2.23pct至9.46%","content_offset":["3345","3365"],"indicators":[{"indicator_name":"研发费用占比","indicator_value":["9.46%","3360","3365"],"indicator_element":{"时间":["2020年","3435","3440"],"公司":["昊海生科","5002","5006"]},"indicator_supplement":{"属性":""}}]}]}